| Publisher’s Note: Join Fierce Biotech Editors and industry leaders at the Fierce Biotech Summit to network and gain exclusive insights. Don’t miss out — register now! |
|
Join IQVIA Patient Suite experts Kevin Landells and Anthony Mikulaschek in this webinar as they explore the flexibility in choosing the right approach for integrating patient technology into your next trial. Whether you opt for an integrated solution or individual technology products, this webinar will guide you through the decision-making process to ensure you’re executing a patient technology strategy that fits your needs. 
|
|
Today’s Big NewsAug 29, 2024 |
|
Shape the Future of Life Sciences Entries for the Fierce Life Sciences Innovation Awards are coming to a close September 5th, 2024. Submit your entry & lead the charge in life sciences innovation. Enter now! 
|
|
| By Nick Paul Taylor Johnson & Johnson has taken another step toward realizing a return on its $6.5 billion nipocalimab bet, filing for FDA approval to challenge argenx and UCB for the generalized myasthenia gravis (gMG) market. |
|
|
|
By James Waldron Repare Therapeutics is laying off a quarter of its workforce as the oncology biotech scales back its preclinical work to focus on more advanced candidates such as a synthetic lethal drug handed back by Roche earlier this year. |
By Fraiser Kansteiner The investment program, which combines the powers of the U.K.'s Department of Health and Social Care, England’s National Health Service and local trade group ABPI, has snared an up to 400 million pound sterling ($527 million) investment to help accelerate patient access to cutting-edge drugs, bolster clinical trials and improve medicines manufacturing in the country. |
Sponsored by InMed Pharmaceuticals New disease-modifying drugs, biological pathways and blood-based biomarker tests are among the rapid changes shaping the Alzheimer’s disease landscape |
|
Luminex MAP profiles
Ultrasensitive Simoa
Olink Target 48 Cytokine 
|
|
By James Waldron Gain Therapeutics has set its sights on proving the effectiveness of its Parkinson’s therapy next year after the brain-penetrant small molecule demonstrated “peripheral target engagement” in a phase 1 trial. |
Sponsored by Bio-Rad Laboratories In this episode of The Top Line, sponsored by Bio-Rad, Dipika Gurnani delves into the challenges and solutions of quantifying HEK293 DNA in biotherapeutics, a field revolutionizing healthcare for over 350 million patients worldwide. |
By Gabrielle Masson,Darren Incorvaia,Max Bayer We really didn't want to have to create another Layoff Tracker this year. But here we are, launching the third annual iteration tracking biopharma layoffs. |
By Darren Incorvaia Proteins are made of chains of amino acids, and a basic tenet of biology is that the sequence of amino acids determines how a protein folds into a 3D shape which, in turn, dictates the protein’s function. But another tenet of biology is that rules are meant to be broken. |
By Darren Incorvaia The effort to develop psychedelic therapies took a hit earlier this month when the FDA rejected Lykos Therapeutics’ MDMA-assisted therapy, a blow that was quickly followed by the retraction of three Lykos research papers and the slashing of 75% of the biotech’s workforce. |
By Angus Liu A Merck & Co. effort to move its PD-1 behemoth Keytruda into early treatment of lung cancer has reached a dead end, along with another bid to expand into a type of early-stage skin cancer. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we look at the potential effects of the Chevron overturn on the biopharma industry. |
|
|---|
|
|
Whitepaper Finding an effective epilepsy treatment can be arduous. Download this brochure to delve into how IQVIA's expertise and innovative strategic approach can streamline the clinical trial process, helping to get new therapies to patients who need them sooner. Sponsored by: IQVIA |
Whitepaper This paper explores the costs of setting up a supply chain in Europe for a new biopharma therapy. It outlines key cost drivers & the various levers decision makers can use to affect those costs. Sponsored by: AIM |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
